secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001104659-23-009939
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio discloses ~$0.34/shr special dividend, 25.2% stake in combined company in Carisma merger
--------------------------------------------------------------------------------

- Expected one-time cash dividend of ~$70M ($0.34/shr) upon merger close; plus CVR up to $0.14/shr from legacy asset sales and Roche milestone.
- Sesen Bio stockholders to own 25.2% of combined company valued at $357M, led by Carisma management.
- Board conducted 4-month strategic review, contacted 100+ parties, received 42 bids; determined merger maximizes value vs dissolution.
- In dissolution scenario, estimated initial distribution only $0.40-$0.60/shr, available after 6+ months, full process up to 3 years.
- Special stockholder meeting on March 2, 2023; Sesen Bio urges vote 'FOR'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923009939/0001104659-23-009939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923009939/tm235275d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-009939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer